Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)NewsBilanz/GuVDividende/HVZertifikateDepot/Watchlist
Times + SalesChart-AnalyseAnalysenSchätzungenTermineOptionsscheinemyHome
BörsenplätzeChartvergleichKursziele ProfilKnock-OutsSenden
OrderbuchRealtime StuttgartFundamentalanalyse InsidertradesFonds 
HistorischRealtime PushmyNews im ForumAnleihen
Kaufen
Verkaufen
  • Sprache:
  • Alle
  • DE
  • EN
  • Sortieren:
  • Datum
  • meistgelesen
02.04.14
STALLERGENES meldet FDA-Zulassung von ORALAIR®, der ersten sublingualen Immuntherapietablette zur Behandlung von Graspollenallergien (Businesswire)
02.04.14
STALLERGENES Announces FDA Approval of ORALAIR®, the First Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy (Businesswire)
05.03.14
Appointment of Christian Chavy as Chief Executive Officer of Stallergenes (Businesswire)
05.03.14
Stallergenes Posts Revenue Growth of 3.5% in 2013 and Increases Its Profitability (EBITDA: €71.3 Million, up 2.8%) (Businesswire)
03.02.14
Stallergenes Reports Positive Results in the Phase II / III Clinical Trial of House Dust Mite Immunotherapy Tablets in Japan (Businesswire)
11.12.13
FDA Advisory Committee Supports Approval of STALLERGENES’ ORALAIR® for the Treatment of Grass Pollen Allergy (Businesswire)
02.12.13
STALLERGENES and ActoGeniX to Develop Together an Innovative New Class of Oral Treatments for Allergy (Businesswire)
31.10.13
GREER® Laboratories, Inc. and STALLERGENES Sign Exclusive Agreement for United States Commercialization Rights to Oralair® (Businesswire)
21.10.13
Stallergenes : Q3 Revenue Growth of 3.6%, Driven by Positive Performance of Sublingual Immunotherapy Treatments (Businesswire)
18.10.13
Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen (Businesswire)
25.07.13
Stallergenes : Half-Year Revenues and Results (Businesswire)
16.05.13
Stallergenes and DBV Technologies Enter into Partnership for the Development of Innovative Treatment of Respiratory Allergies (Businesswire)
22.04.13
Stallergenes’ Q1 Revenue Stable (-0.4%) with Very Strong Growth of Oralair (+58%) and Continuous Expansion in International Markets (+39%) (Businesswire)
08.03.13
Stallergenes S.A.: Commercialization of Oralair in the US: Possible Cooperation with Greer Laboratories, Inc. (Businesswire)
07.03.13
Stallergenes Announces 2012 EBITDA of €69.3 Million, up 8% and Net Cash Flow Growth of 80% at €20.4 Million (Businesswire)
19.02.13
Stallergenes Investor Day (Businesswire)
18.02.13
Stallergenes Announces FDA Acceptance for Review of Its BLA for Oralair, 5-Grass Pollen Extract AIT Sublingual Tablet (Businesswire)
14.01.13
Stallergenes 2012 Sales Grew at 3.3% with Strong Growth in the International Business (28%) (Businesswire)
22.11.12
Stallergenes Launches Oralair® in France, the Only Immunotherapy Tablet with 5 Grass Pollen Tailored to the Epidemiology and Patients’ Expectations (Businesswire)
10.10.12
Stallergenes: Cumulative Sales Growth of 4.3% to End September (Businesswire)
11.09.12
STALLERGENES : 2012 FIRST HALF-YEAR RESULTS (Businesswire)
28.08.12
Stallergenes and Aerocrine Sign Exclusive Distribution Agreement for NIOX MINO®, an Innovative Device to Allow Better Diagnosis and Monitoring of Asthma (Businesswire)
12.07.12
Stallergenes: 1st Half-Year 2012: Sales up 6% (Businesswire)
13.06.12
Patrick Langlois Appointed Non Executive Chairman of the Board of Directors of Stallergenes (Businesswire)
30.05.12
Stallergenes Makes One Step Forward to the Launch of Oralair® in France (Businesswire)
21.05.12
Stallergenes Remains Committed to the Recognition of Innovative Pharmaceutical Companies and Has Joined G5 Health (Businesswire)
04.05.12
Stallergenes Announces Positive Clinical Results for Its House Dust Mites Immunotherapy Tablet (Businesswire)
12.04.12
Quarterly Information : Stallergenes Continues to Grow (Businesswire)
02.04.12
Stallergenes Has Identified Two Candidate Biomarkers of Early Efficacy of Allergen Immunotherapy (Businesswire)
21.03.12
Stallergenes Continues Its Strategic International Expansion with the Successfull Registration in Canada of Oralair™ Tablet for Grass Pollen (Businesswire)
19.03.12
Stallergenes: 2011 Financial Results (Businesswire)
12.01.12
Stallergenes: 2011 Sales up 9% Market Share Gains (Businesswire)
13.10.11
Stallergenes: 6% Sales Growth for the 3RD QUARTER 2011 vs 2010 - 9% Cumulative Sales Growth to End September (Businesswire)
01.09.11
Stallergenes: First Half-Year Results 2011 (Businesswire)
13.07.11
Stallergenes: 1st Half-Year 2011: Sales Up 10% (Businesswire)
04.07.11
Stallergenes: DSMB1 Recommends the Discontinuation of VO64.08 Study (Actair® in Children) (Businesswire)

Stallergènes News

Stallergènes News: auf dieser Seite finden Sie alle Stallergènes News und Nachrichten zur Stallergènes Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Stallergènes News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Stallergènes News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Meistgelesene Stallergènes News 1M

Keine Nachrichten gefunden.
Weitere Stallergènes News

Stallergènes Peer Group News

Keine Nachrichten gefunden.